1Deeb K K, Trump D L, Johnson C S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics [J]. Nature Reviews Cancer, 2007,7 (9) : 684-700.
2Martin L, Harold L, Newmark D. Vitamin D,calcium and prevention of breast cancer : a review [ J ]. Am Colle J Nutr, 1999,5 (18) :392-397.
3VanHouten J N. Calcium sensing by the mammary gland [J]. J Mammary Gland Biol Neoplasia, 2005,10(2) : 129-139.
4Yamaha K, Saito H, Takenouchi K, et al. Vitamin D and cancer [J]. Clin Calcium, 2006, 16(7) : 1147-1153.
5Barbareschi M, Veronese S, Caffo O, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up [J]. HumPathol, 1996,27( 11 ) : 1149 -1155.
6Issa L L, Leong G M, Eisman J A. Molecular mechanism of vitamin D receptor action [J]. Inflamm Res, 1998,47(12) :451-475.
7Bortman P, Folgueiar M A. Antiprolifematine effet of 25- Hydroxy Vitamin D on breast cells [J]. Braz Med & Bio Res, 2002,35 (1): 1-9.
8Christensen G L, Jepsen J S, Fog C K, et al. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment [J]. Breast Cancer Res Treat,2004,85(1):53-63.
9Li F, Ling X, Huang H, et al. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines [ J ]. Oneogene, 2005,24 (8) : 1385-1395.
10Capiati D A, Rossi A M, Picotto G, et al. Inhibition of serumstimulated mitogen activated protein kinase by lalpha, 25 (OH)2- vitamin D3 in MCF-7 breast cancer ceils [J]. J Cell Biochem, 2004,93 (2) : 384-397.
1Evans SR,Shchepotin El,Young H , et al. 1 , 25-dihydrox-yvitamin D3 synthetic analogs inhibit spontaneous metastasesin a 1,2-dimethylhydrazine-induced colon carcinogenesismodel [J]. Int J Oncol , 2000 , 16 (6) : 1249-1254 .
2Giovannucci E. The epidemiology of vitamin D and cancerincidence and mortality : a review ( United States ) [ J ]. CancerCauses Control,2005,16 (2) : 83-95 .
3Colston KW . Vitamin D and breast cancer risk [ J ]. Best practRes clin Endocrinol metab , 2008 , 22 (4) : 587.
4Christakos S , Dhawan P , Liu Y , et al. New insights intothe mechanisms of vitamin D [ J ]. J cell Biochem,2003,88(4):695.
5Scjwartz GG. Vitamin D and intervention trial in prostatecancer : From theory to therapy [ J]. Ann Epidemiol,2009 , 19(2):96.
6Ren C,Qiu MZ , Wang DS , et al. Prognostic effects of25-hydroxyvitamin D levels in gastric cancer [ J ]. Transl Med ,2012(10):16.
7Fang F,Kasperzyk JL,Shui I , et al. Prediagnostic plasmavitamin D metabolites and mortality among patients withprostate cancer[ J ]. PLoS One,2011,6(4): el8625 .
8Drake MT,Maurer MJ,Link BK , et al. Vitamin D insuffi-ciency and prognosis in non-Hodgkin's lymphoma [ J ]. ClinOncol,2010 , 28(27) : 4191-4198.
9Shanafelt TD , Drake MT , Maurer MJ,et al. Vitamin D in-sufficiency and prognosis in chronic lymphocytic leukemi-aleukemiatJ]. Blood , 2011 , 117(5) : 1492-1498.
10Barbareschi M,Veronese S,Caffo 0 , et al. Bcl-2 and p53expression in node-negative breast carcinoma : a study withlong-term follow-up [J].HumPathol, 1996,27(11): 1149-1155 .
